| RCT | randomized controlled trial |
| MDMA | 3,4-methylenedioxymethamphetamine |
| LSD | lysergic acid diethylamide |
| PTSD | post-traumatic stress disorder |
| MD | major depression |
| AUD | alcohol use disorder |
| MDD | major depressive disorder |
| SUD | substance use disorder |
| BD | bipolar disorder |
| DSM | Diagnostic and Statistical Manual of Mental Disorders |
| ICD | International Classification of Diseases |
| PRISMA | Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
| PICOS | Population, Intervention, Comparator, Outcomes, Study design |
| AMSTAR2 | Assessment of Multiple Systematic Reviews 2 |
| GRADE | Grading of Recommendations Assessment, Development and Evaluation |
| OR | odds ratio |
| RR | risk ratio |
| CI | confidence interval |
| SMD | standardized mean difference |
| ED50 | effective dose for 50% of population |
| ED95 | effective dose for 95% of population |
| MD | mean difference |
| SD | standard deviation |
| ECG | electrocardiogram |
| FDA | Food and Drug Administration |
| CBT | cognitive behavioral therapy |
| SSRIs | selective serotonin reuptake inhibitors |
| CANMAT | Canadian Network for Mood and Anxiety Treatments |
| CAPS | Clinician-Administered PTSD Scale |
| BDI | Beck Depression Inventory |
| SDS | Sheehan Disability Scale |
| PSQI | Pittsburgh Sleep Quality Index |
| DES | Dissociative Experiences Scale |
| ADR | adverse drug reaction |
| AE | adverse event |